Trusted Resources: Evidence & Education
Scientific literature and patient education texts
Stress Triggers the Onset and the Recurrences of Hyperthyroidism in Patients With Graves’ Disease
authors: Vita R, Lapa D, Trimarchi F, Benvenga Ssummary/abstract:
The aim of this study was to evaluate the relationship of stressful events (SE) with the onset and outcome of Graves’ disease (GD). Over a period of 21 years, we enrolled 58 consecutive patients in whom at least one SE had occurred <=12 months before the onset of GD. Patients were treated with antithyroid drugs (ATD) for >=12 months and followed up for >=5 years after ATD withdrawal. We divided patients in three groups: REM (who reached remission; 25.9%); EXA (who experienced >=1 exacerbation during ATD; 10.3%); and REL (who experienced >=1 relapse after ATD withdrawal; 63.8%).
The average age at onset was similar in the three groups. All males aged <=25 years at GD onset relapsed at least once; no patient aged >=51 years at GD onset relapsed >=2 times. All patients who exacerbated or relapsed had at least one SE preceding each exacerbation or relapse. The time lag between SE and onset of GD (19.3±11.9 weeks) correlated with the age at onset (r=0.292, P=0.0002), particularly in the REL group (r=0.346, P=0.001). Overall, EXA and REL patients experienced more SE than REM patients (P=0.0002 and P=0.003, respectively). In the REL group, the overall number of SE was correlated with the number of relapses (r=0.486, P<0.0001).
There exist GD patients who are prone to develop hyperthyroidism and its recurrences when exposed to SE. They are relatively young; the younger these patients are, the shorter is the time lag between SE and the onset of hyperthyroidism.organization: University of Messina, Italy
Reversible Pulmonary Hypertension and Clinical Right Heart Failure Associated With Graves’ DiseaseBackground: Heart failure is typically ...
Most Patients With Graves’ Disease Treated With Antithyroid Drugs Eventually Require Additional TherapiesGraves’ disease is the most common cau...
Graves’ Disease After Treatment With Alemtuzumab for Multiple SclerosisContext: Alemtuzumab, a humanized monoc...
Radioiodine Therapy for Juvenile Graves’ Disease: A Single Institution Experience in Japan (Poster 317)131I radioiodine therapy (RIT) has been ...
Risk Factors of Hepatic Dysfunction in Patients With Graves’ Hyperthyroidism and the Efficacy of 131iodine Tre...Hepatic dysfunction is often observed in...
Can We Predict Relapse in Graves’ Disease? Results From a Systematic Review and Meta-AnalysisBackground: Identification of pretreatm...
Treatment of Graves’ Disease – An OverviewHyperthyroidism may be defined as the ex...
The cookie settings on this website are set to "allow cookies" to give you the best browsing experience possible. If you continue to use this website without changing your cookie settings or you click "Accept" below then you are consenting to this.